Paris, France, 19 December 2024 – Astraveus SAS (“Astraveus” or the “Company”), the Benchtop Cell Factory company aiming for maximized cell quality and order-of-magnitude cost reduction in cell therapy manufacturing, today announces that the Company has been awarded a non-dilutive funding of €7.1M by the French State. The funding is part of French State’s France 2030 investment program, a future-focused fund that champions next-generation innovation and business growth to enhance economic competitiveness and entrepreneurship.
Astraveus secured the funding through a successful application to the “Première usine” [first factory] competitive call for projects launched by Bpifrance, which aims to accelerate the emergence of first industrialization successes by start-ups. The funds will enable the establishment of manufacturing infrastructure for innovative microfluidic consumables at Astraveus to further accelerate the company’s mission to revolutionize cell therapy processing through the launch of the Lakhesys Benchtop Cell Factory™. The strategic development aligns with Astraveus’ mission to provide more accessible, cost-effective therapies to patients globally, thus enabling a healthier tomorrow.
Jérémie Laurent, PhD, CEO of Astraveus, commented: “This additional funding awarded by the French State through its France 2030 program is a testament to our innovative approach and dedication to revolutionizing cell therapy manufacturing. We are thrilled to charge forward in establishing our industrialization infrastructure in Paris and propel our mission to make cell therapy more accessible, efficient, and scalable.”
For further information, please contact:
Astraveus SAS
Jérémie Laurent, Chief Executive Officer